行情

INSM

INSM

Insmed
NASDAQ

实时行情|Nasdaq Last Sale

26.63
+0.62
+2.38%
盘后: 26.63 0 0.00% 16:07 09/21 EDT
开盘
26.19
昨收
26.01
最高
27.08
最低
25.85
成交量
56.72万
成交额
--
52周最高
45.44
52周最低
22.00
市值
30.57亿
市盈率(TTM)
-7.4276
分时
5日
1月
3月
1年
5年
Insmed Incorporated(纳斯达克股票代码:INSM)的内在计算表明它被低估了 36%
How far off is Insmed Incorporated ( NASDAQ:INSM ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 09/10 13:18
Insmed 首席合规官交易了 730.57 万美元的公司股票
John Soriano, Chief Compliance Officer at Insmed (NASDAQ:INSM), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that John Sori...
Benzinga · 09/09 23:13
内幕交易:Insmed
MT Newswires · 09/09 16:22
史蒂文科恩通过 Theravance Biopharma Stake 提高医疗保健曝光率
GuruFocus News · 09/08 20:55
Insmed 参加九月五次会议
/PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor e...
PR Newswire - PRF · 09/01 12:00
Insmed 资本使用洞察的回报
After pulling data from Benzinga Pro it seems like during Q2, Insmed (NASDAQ:INSM) brought in sales totaling $45.37 million. However, earnings decreased 5.65%, resulting in a loss of $88.57 million.
Benzinga · 08/27 21:14
Endurant Capital Management LP 收购 Cigna Corp、Icon PLC、Thermo Fisher Scientific Inc,出售...
GuruFocus News · 08/27 16:38
Novo A 收购 Edgewise Therapeutics Inc、Cyteir Therapeutics Inc、Bolt Biotherapeutics Inc,出售...
GuruFocus News · 08/18 13:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解INSM最新的财务预测,通过INSM每股收益,每股净资产,每股现金流等数据分析Insmed近期的经营情况,然后做出明智的投资选择。
分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测INSM价格均价为51.78,最高价位58.00,最低价为41.00。
EPS
机构持股
总机构数: 299
机构持股: 1.37亿
持股比例: 119.43%
总股本: 1.15亿
类型机构数股数
增持
86
2,111.82万
建仓
29
316.27万
减持
50
583.33万
平仓
24
278.29万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.35%
制药与医学研究
+0.70%
高管信息
Chairman/President/Chief Executive Officer/Director
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Senior Vice President/General Counsel
Michael Smith
Chief Compliance Officer
John Soriano
Other
Martina Flammer
Other
S. Nicole Schaeffer
Lead Director/Independent Director
David Brennan
Independent Director
Alfred Altomari
Independent Director
Elizabeth Anderson
Independent Director
Clarissa Desjardins
Independent Director
Steinar Engelsen
Independent Director
Leo Lee
Independent Director
David McGirr
Independent Director
Carol Schafer
Independent Director
Melvin Sharoky
暂无数据
INSM 简况
Insmed Incorporated是一家全球性的生物制药公司。该公司的产品阿米卡星脂质体吸入悬浮液(ARIKAYCE)开发用于治疗鸟分枝杆菌复合体(MAC)肺病,作为成人患者联合抗菌药物治疗方案的一部分,是一种必须或可选择的治疗方案。该公司的早期临床管道包括INS1007,一种新的口服可逆抑制剂二肽基肽酶1,具有治疗非囊性纤维化支气管扩张和其他炎性疾病的潜力.该公司还生产INS1009,一种吸入制剂的曲前列环素前药,提供差异化的产品特征,用于治疗包括肺动脉高压的罕见肺部疾病。

微牛提供Insmed Incorporated(NASDAQ-INSM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的INSM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易INSM股票基本功能。